Mergers & Acquisitions ·
Rallybio postpones $1.50 per share cash distribution to Avenzo merger due to listing approval delays
RLYBRallybio Corp
Rallybio Corp has postponed the closing of its merger with Avenzo Therapeutics, Inc., originally scheduled for November 6, 2026, because conditions related to the listing of Rallybio's shares have not been satisfied. Consequently, the company did not deposit funds for the previously announced $1.50 per share cash distribution to Avenzo shareholders on November 5, 2026. The payment date and ex-dividend date for this distribution are now delayed pending further updates. Rallybio Corp operates in the biotechnology industry.